Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

View Slides

Literature Highlights - November 2024

more…

Keywords:

systemic lupus erythematosus, randomized clinical trial, belimumab, disease activity, patient-reported outcomes, disease trajectories, Efficacy, Iberdomide, Phase 2, Safety, CLE,, SLE, Type 2 diabetes, Cardiovascular, Renal, SGLT2i

January 2023

Publication thumbnail: Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial

View Slides

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial

ACR Open Rheumatol. 2023;5(1):38–48 doi: 10.1002/acr2.11511

Results of a phase II trial of evobrutinib suggest that Bruton's Tyrosine Kinase (BTK) inhibition is not an efficacious therapeutic intervention over standard of care therapy for patients with SLE.

more…